Q-omics provides the consensus-scored NLRP2 profile across patient tissues and cancer cell-line models. NLRP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, NLRP2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, NLRP2 protein abundance shows 16,889 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight PAAD, KIRC, and LUAD as cancer lineages where NLRP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP2 survival associations across molecular data types. NLRP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP2 RNA expression–survival associations across cancer types. High NLRP2 expression shows unfavorable associations in PAAD, UCS, UCEC and SCLC, but favorable associations in SKCM and KICH. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for NLRP2 RNA expression.
This table summarizes NLRP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NLRP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP2 shows lower tumor expression in KIRC, KICH, HNSC, THCA and COAD and higher tumor expression in UCEC. The KIRC box plot shows higher NLRP2 RNA expression in normal versus tumor tissue (log2 FC = −1.710, t-test p < 0.001).
This table shows molecular features associated with NLRP2 in patient tissues and cancer cell lines. In patient samples, NLRP2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
